Publications by authors named "J M Sanchez-Hidalgo"
Article Synopsis
- Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with late diagnoses and ineffective treatments, making surgery the only potential cure for early-stage patients.
- Recent research found that splicing machinery components, particularly PRPF8 and RBMX, are dysregulated in PDAC, correlating with worse patient outcomes and tumor characteristics.
- Modulating these splicing factors in cancer cell lines normalized their expression levels and reduced tumor-related features, suggesting they could be potential targets for new therapies in PDAC.
Background: Simultaneous pancreas-kidney transplantation is the optimal treatment for patients with type 1 diabetes and renal failure. The use of pancreas grafts from donation after circulatory death (DCD), using normothermic regional perfusion (NRP), is still marginal worldwide, mainly due to possible additional risks of graft dysfunction and complications compared with grafts from donors after brain death.
Methods: Case series of patients who underwent simultaneous pancreas-kidney transplantation after DCD-NRP between January 2018 and September 2022.
Correction: Laparoscopic versus open approach for interval cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced epithelial ovarian cancer: a matched comparative study.
Surg Endosc
January 2024
Laparoscopic versus open approach for interval cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced epithelial ovarian cancer: a matched comparative study.
Surg Endosc
January 2024
Background: The use of the laparoscopic approach for the treatment of carcinomatosis from epithelial ovarian cancer (EOC) is controversial. The aim of this study was to compare the short-term outcomes of both laparoscopic and open approach for interval CRS+HIPEC in a matched cohort of patients with advanced EOC.
Methods: A retrospective analysis of a prospectively maintained database including 254 patients treated with interval CRS-HIPEC between January 2016 and December 2021 was performed.
Introduction: Neutral argon plasma (NAP) system could meet the requirements to achieve oncological cytoreduction of peritoneal carcinomatosis with miliary lesions, minimizing the associated morbidity. This phase I/II trial aims to establish the desirable dose that is safe and effective in eliminating tumor cells with lower penetration.
Methods: Patients diagnosed with different origins for peritoneal carcinomatosis and miliary implants were selected for the study.